Results 11 to 20 of about 177,264 (261)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements [PDF]

Molecules, 2023
This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements.
Oana Ramona Cătălina Gheorghiu, Anne Marie Ciobanu, Claudia Maria Guțu, Carmen Lidia Chițescu, Giorgiana Valentina Costea, Daniela Mădălina Anghel, Ana Maria Vlasceanu, Daniela Luiza Baconi   +7 more
doaj   +5 more sources

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review [PDF]

Journal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso, João Crispim Ribeiro, Eduardo P. Miranda   +2 more
doaj   +3 more sources

Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study. [PDF]

Neurology
Background and Objectives Repurposing phosphodiesterase type 5 inhibitors (PDE5Is) as drugs for Alzheimer disease (AD) risk reduction has shown promise based on animal studies. However, evidence in humans remains inconclusive.
Adesuyan M, Jani YH, Alsugeir D, Howard R, Ju C, Wei L, Brauer R.   +6 more
europepmc   +4 more sources

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. [PDF]

Cell Rep Med, 2022
Summary The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by cancer cell extrinsic mechanisms of the tumor microenvironment (TME).
Sharpe BP, Hayden A, Manousopoulou A, Cowie A, Walker RC, Harrington J, Izadi F, Breininger SP, Gibson J, Pickering O, Jaynes E, Kyle E, Saunders JH, Parsons SL, Ritchie AA, Clarke PA, Collier P, Mongan NP, Bates DO, Yacqub-Usman K, Garbis SD, Walters Z, Rose-Zerilli M, Grabowska AM, Underwood TJ.   +24 more
europepmc   +4 more sources

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors [PDF]

Pulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake   +6 more
doaj   +3 more sources

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews [PDF]

Frontiers in Pharmacology, 2021
Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes.
Nikolaos Pyrgidis, Nikolaos Pyrgidis, Ioannis Mykoniatis, Ioannis Mykoniatis, Anna-Bettina Haidich, Maria Tirta, Persefoni Talimtzi, Dimitrios Kalyvianakis, Dimitrios Kalyvianakis, Andreas Ouranidis, Andreas Ouranidis, Dimitrios Hatzichristou, Dimitrios Hatzichristou   +12 more
doaj   +3 more sources

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review [PDF]

International Journal of Retina and Vitreous, 2020
To provide information on the effects of phosphodiesterase type 5 (PDE5) inhibitors on choroidal vessels and central serous chorioretinopathy (CSC) and possible implications for development of exudative age-related macular degeneration (AMD).
Natasha Ferreira Santos da Cruz, Murilo Ubukata Polizelli, Laís Maia Cezar, Emmerson B. Cardoso, Fernando Penha, Michel Eid Farah, Eduardo B. Rodrigues, Eduardo A. Novais   +7 more
doaj   +3 more sources

Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch? [PDF]

ESC Heart Failure, 2021
E. Wilson Grandin, Jeffrey J. Teuteberg
doaj   +4 more sources

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design [PDF]

ESC Heart Failure, 2020
Aims In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance.
Pascal Amedro, Arthur Gavotto, Hamouda Abassi, Marie‐Christine Picot, Stefan Matecki, Sophie Malekzadeh‐Milani, Marilyne Levy, Magalie Ladouceur, Caroline Ovaert, Philippe Aldebert, Jean‐Benoit Thambo, Alain Fraisse, Marc Humbert, Sarah Cohen, Alban‐Elouen Baruteau, Clement Karsenty, Damien Bonnet, Sebastien Hascoet, SV‐INHIBITION study investigators   +18 more
doaj   +3 more sources

A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure. [PDF]

PLoS ONE, 2020
Minimizing the toxicity of radiotherapy is challenging. We investigated the effects of a phosphodiesterase type-5 inhibitor (PDE5I) on the urinary bladder after pelvic radiotherapy.
Hee Youn Kim, Dong Sup Lee
doaj   +4 more sources